000			01713 a2200445 4500
005			20250515130643.0
264		0	_c20090115
008			200901s 0 0 eng d
022			_a0028-3908
024	7		_a10.1016/j.neuropharm.2008.06.053 _2doi
040			_aNLM _beng _cNLM
100	1		_aStramiello, Michael
245	0	0	_aD1/5 receptor-mediated enhancement of LTP requires PKA, Src family kinases, and NR2B-containing NMDARs. _h[electronic resource]
260			_bNeuropharmacology _cOct 2008
300			_a871-7 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural
650	0	4	_a2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine _xpharmacology
650	0	4	_aAnimals
650	0	4	_aAnimals, Newborn
650	0	4	_aCyclic AMP-Dependent Protein Kinases _xphysiology
650	0	4	_aDopamine Agonists _xpharmacology
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Interactions
650	0	4	_aElectric Stimulation _xmethods
650	0	4	_aEnzyme Inhibitors _xpharmacology
650	0	4	_aHippocampus _xdrug effects
650	0	4	_aIn Vitro Techniques
650	0	4	_aLong-Term Potentiation _xdrug effects
650	0	4	_aMale
650	0	4	_aPhenols _xpharmacology
650	0	4	_aPiperidines _xpharmacology
650	0	4	_aRats
650	0	4	_aRats, Sprague-Dawley
650	0	4	_aReceptors, Dopamine D1 _xphysiology
650	0	4	_aReceptors, N-Methyl-D-Aspartate _xantagonists & inhibitors
650	0	4	_asrc-Family Kinases _xphysiology
700	1		_aWagner, John J
773	0		_tNeuropharmacology _gvol. 55 _gno. 5 _gp. 871-7
856	4	0	_uhttps://doi.org/10.1016/j.neuropharm.2008.06.053 _zAvailable from publisher's website
999			_c18124319 _d18124319